Discover and read the best of Twitter Threads about #geriheme
Most recents (8)
Abs 694: Dr Puiz presents GEM-Claridex trial of Rd vs Clarithromycin-RD. Got to witness Sweet moment at end when her mentor @mvmateos flashed her the “Great job, my protege!” smile we all need to see ❤️ 
GEM-Clarieex provides another cautionary tale about a myeloma regimen that is more effective but more toxic in older patients #geriheme....
Very inclusive with pts into their 90s. Significantly greater CR, >=VGPR rates. We should celebrate 🎉 right? But....
Abs 380: Geriatric assessment incorporated into a real transplant workflow. Took only 5-6 minutes of provider time! And see thread for what that 5-6 min tells you...
#ASH19 #geriheme grants.nih.gov/grants/guide/p…
#ASH19 #geriheme grants.nih.gov/grants/guide/p…
Survival: lower OS with impairment on Timed Up and Go
Here's my #gerihemelist for #ASH19 Saturday...
Abs 2209, Poster today: 1/3 of pts with "good" PS were frail; Frail pts with AML had 50% 100-day mortality! ash.confex.com/ash/2019/webpr…
Abs 1563, poster today: In SEER-Medicare analysis of 2800 older adults with Hodgkin Lymphoma (1999-2014), 1/4 received NO treatment.
#ASH19 #geriheme ash.confex.com/ash/2019/webpr…
#ASH19 #geriheme ash.confex.com/ash/2019/webpr…
Abs 268: @HiraSMian presents data on >5700 pts with MM from Canadian registry with some good/some sobering news for #geriheme pts:
1. ASCT use rising
2. 60% of older pts get a novel drug
3. 20% 1-yr mortality
4. 30% of older patients received NO MYELOMA TREATMENT
#ASH19
1. ASCT use rising
2. 60% of older pts get a novel drug
3. 20% 1-yr mortality
4. 30% of older patients received NO MYELOMA TREATMENT
#ASH19
Even with universal coverage, older pts, lower SES or more comorbidities less likely to be treated for myeloma #mmsm #geriheme #ASH19
High 1-yr mortality for older pts with myeloma who don’t receive treatment. We saw similar rate untreated in SEER- Medicare database. #geriheme ncbi.nlm.nih.gov/m/pubmed/29429…
Abs 71: Trends in early mortality (<6 mos) in myeloma - SEER analysis of >90K pts 1975-2015 with Joinpoint regression -> change in trend for early mortality.
ash.confex.com/ash/2019/webpr…
#mmsm #ASH19
ash.confex.com/ash/2019/webpr…
#mmsm #ASH19
Older pts with MM at greater risk for early mortality (OR 4.8 for Age >79).
#geriheme
#geriheme
Abs 69: Vulnerable Elders Survey-13 in cohort of >2000 patients in the Lymphoma Epidemiology Outcome cohort.
28% of pts were vulnerable by VES13. Pts more likely to be vulnerable if they completed VES13 after treatment
ash.confex.com/ash/2019/webpr… #ASH19 #geriheme @MaurerStats
28% of pts were vulnerable by VES13. Pts more likely to be vulnerable if they completed VES13 after treatment
ash.confex.com/ash/2019/webpr… #ASH19 #geriheme @MaurerStats
@MaurerStats Vulnerable pts had poorer OS (HR ~5) *** independent of performance status***. PS is not enough! #ASH19 #geriheme
@MaurerStats Moderator question: How to use this info? Answer: good tool to screen for need for geriatric assessment
Abstract 67: all new patients with blood cancer age >=75 screened for frailty; participants randomized to receive geriatric consultation. Outcomes: feasibility, 1-yr OS, acute care utilization, goals of care discussion. ash.confex.com/ash/2019/webpr…
1. 2 out of 5 real-world myeloma patients ineligible for clinical trials; 75% of frail patients ineligible.
ash.confex.com/ash/2019/webpr…
#GeriHemeList
ash.confex.com/ash/2019/webpr…
#GeriHemeList
2. Response rates in frail patients similar to those in intermediate or fit transplant-ineligible NDMM patients
ash.confex.com/ash/2019/webpr…
#GeriHemeList
ash.confex.com/ash/2019/webpr…
#GeriHemeList
